JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June 22, 2022.
| Title: | Quotient Fourth Quarter and Full Year 2021 Financial Results and Conference Call |
| Speakers: | Manuel O. Méndez, Chief Executive Officer Ali J. Kiboro, Chief Financial Officer |
| Date: | Wednesday, June 22, 2022 |
| Time: | 8:00am ET/ 14:00 CET |
| Conference Call Dial-in Details: |
International: 201-689-8560 Switzerland: 0800 835 525 United Kingdom: 0800 756 3429 US: 877-407-0784 Conference ID: 13729874 |
| Webcast: | Webcast Link – Click Here Quotient Events & Presentations |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that it believes reshape the way diagnostics are practiced. The MosaiQ solution, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. The MosaiQ solution is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient’s operations are based in Switzerland, Scotland, US and the UAE.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Investor Relations, ir@quotientbd.com; +41 22 545 52 26
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF…
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX:…
WESTBROOK, ME / ACCESSWIRE / June 7, 2024 / What Happened?We discovered unauthorized access on…